Millions of people are injecting themselves weekly with a drug that can cause sudden, permanent blindness — and most of them have no idea. A new study links Wegovy to a rare but devastating condition called nonarteritic anterior ischemic optic neuropathy — an “eye stroke” that cuts off blood flow to the optic nerve. You wake up one morning and your vision is just gone.
What Is an Eye Stroke, Exactly?
Let’s be clear about what we’re talking about. Nonarteritic anterior ischemic optic neuropathy — NAION for short — is not a metaphor. It’s not temporary. Blood flow to the optic nerve gets interrupted. The nerve tissue dies. Vision loss follows. Sometimes partial. Sometimes catastrophic. And in many cases, it doesn’t come back.
It’s rare. That matters. But “rare” means something different when the drug in question has been prescribed to over 40 million people globally. Do the math. Even a fractional percentage of 40 million is a very large number of people potentially going blind.
Researchers found that patients using semaglutide — the active ingredient in both Wegovy and Ozempic — had significantly higher rates of NAION compared to people on other weight loss or diabetes medications. This wasn’t a tiny signal in noisy data. It was consistent enough to raise serious flags.
The GLP-1 Gold Rush
Semaglutide is the hottest drug on the planet right now. Wegovy for weight loss. Ozempic for type 2 diabetes. Both manufactured by Novo Nordisk, which has spent the last two years swimming in money as demand outpaced supply. Wall Street fell in love. Celebrities talked about it openly. Doctors wrote prescriptions like confetti at a parade.
The weight loss results are real. Nobody serious disputes that. People drop significant body weight. Appetite suppression works. For people battling obesity-linked conditions — heart disease, sleep apnea, joint damage — the benefits can be life-changing.
But the euphoria around GLP-1 drugs created a cultural moment where skepticism felt almost contrarian. Asking hard questions about side effects was treated like being anti-vaccine. That’s a dangerous place to be with any pharmaceutical product, no matter how promising.
What We Already Knew
The side effect profile of semaglutide was never exactly clean. Nausea. Vomiting. Gastroparesis — where the stomach essentially stops moving food properly. Pancreatitis risk. Muscle mass loss alongside fat loss. These were documented. Discussed. Often minimized.
The eye stroke connection is newer and more alarming precisely because vision loss hits differently in the public imagination. People accepted stomach cramps. They accepted some muscle wasting. Sudden blindness is a different category of consequence entirely.
This is also happening inside a broader conversation about how fast we moved with these drugs. The tech policy world has wrestled with similar questions — about AI deployment, about safety testing timelines, about who bears the cost when things go wrong. Check out the December 2025 US Tech Policy Roundup for a sense of how regulators are increasingly thinking about speed versus safety across high-stakes sectors. Pharma and tech are more alike than either industry wants to admit.
Who’s Actually at Risk?
The research suggests certain populations carry higher baseline risk for NAION — people with diabetes, high blood pressure, sleep apnea, and those who are obese. Here’s the cruel irony: those are exactly the people Wegovy and Ozempic are prescribed to most aggressively.
The drug is treating a condition while potentially worsening the risk factors for a separate, severe complication. That’s not a reason to ban it. But it is a reason to have an honest, uncomfortable conversation that the pharmaceutical industry and its cheerleaders have been slow to initiate.
Doctors need to be upfront with patients before the first injection, not after a vision scare lands someone in an emergency room. Informed consent isn’t a checkbox. It’s a responsibility.
The Hot Take
The FDA should have required longer-term safety studies before Wegovy became a lifestyle drug for people who are 20 pounds overweight. We rushed this. The clinical trials were solid for their scope — but scope is the problem. The drug hit tens of millions of people before the long tail of rare side effects had time to surface in the data. We essentially ran a population-scale experiment and called it medicine. The eye stroke data is just the latest reminder that “approved” and “fully understood” are not the same thing, and we keep pretending they are.
Where This Leaves Patients
If you’re on semaglutide right now, don’t panic. Don’t flush it. Talk to your doctor — a real conversation, not a three-minute telehealth check-in. Ask specifically about your personal risk factors for NAION. Ask what symptoms should prompt an immediate call. Get your eyes checked if you haven’t recently.
The same critical thinking that good investors apply to mixed signals in the market — like the kind Seth R Freeman unpacks when markets keep pricing in AI growth despite murky earnings data — applies here. Don’t let narrative overwhelm evidence. Don’t let enthusiasm substitute for scrutiny.
Wegovy is not evil. But it’s also not magic. It’s a powerful drug with real consequences, prescribed at historic scale, still revealing what it does to the human body over time. The people taking it deserve honesty from the industry that profits from them — and from the media that spent two years writing breathless coverage without asking nearly enough hard questions.